Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Promotes anchorage-independent cell growth and tumor formation (By similarity). Additionally we are shipping KIAA1524 Kits (6) and KIAA1524 Proteins (3) and many more products for this protein.
Showing 10 out of 38 products:
CIP2A levels were significantly associated with the American Joint Committee on Cancer (AJCC) stage, histological grade and lymph node metastasis in breast cancer patients.
CIP2A is a tumor-associated autoantigen in lung cancer, which promote lung cancer proliferation partially through MKK4 (show MAP2K4 Antibodies)/7-JNK (show MAPK8 Antibodies) signaling pathway.
CIP2A is a critical oncoprotein involved in cell invasion and epithelial mesenchymal transition in clear cell renal carcinoma (show TSC2 Antibodies).
Identify CIP2A as a common denominator for androgen receptor (show AR Antibodies)-signaling and prostate cancer stem cell functionality, and suggest as possible therapeutic target.
CIP2A was detected in tongue cancer and tongue hyperplasia, whereas local inflammation was stronger in cancer, CIP2A expression was increased in metastasized cancer compared to non-metastasized
CIP2A is an independent prognostic marker in patients with wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy.
CIP2A regulates cancer metabolism and CREB (show CREB1 Antibodies) phosphorylation in non-small cell lung cancer
Data show that afatinib reduced Elk-1 (show ELK1 Antibodies) transcription factor binding to the CIP2A protein promoter and suppressed CIP2A transcription.
we provide a novel therapeutic mechanism for inhibiting CIP2A function in cancerous cells via targeting the CIP2A-LRRC59 interaction.
our findings strongly suggest that CIP2A promotes cell cycle progression, premature chromosome segregation, and aneuploidy, possibly through a novel interaction with Sgol1 (show SGOL1 Antibodies).
Knockdown of CIP2A by stable CIP2A siRNA transfection inhibited MDA-MB-231 cell proliferation, invasion, colony growth in vitro, and xenograft growth and metastasis in vivo of breast cancer in mice.
CIP2A as a hitherto unrecognized mediator of T-cell activation.
Downregulation of CIP2A suppresses cell proliferation and growth of nasopharyngeal carcinoma.
CIP2A strongly interacts with NEK2 (show NEK2 Antibodies) during G2/M phase, thereby enhancing NEK2 kinase (show NEK2 Antibodies) activity to facilitate centrosome separation in a PP1 (show PPP1CC Antibodies)- and PP2A (show PPP2R2B Antibodies)-independent manner.
Data show that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies.
Loss of CIP2A in Myc (show MYC Antibodies)-overexpressing neural progenitor cells significantly reduces the ability of Myc (show MYC Antibodies) to increase self-renewal and proliferation.
Promotes anchorage-independent cell growth and tumor formation (By similarity).
protein CIP2A homolog
, CONSTANS interacting protein 2a
, hypothetical protein LOC100216050
, cancerous inhibitor of PP2A
, p90 autoantigen
, protein CIP2A
, p90 autoantigen homolog